We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-2.31%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$301M
AUM Growth
-$41.3M
Cap. Flow
+$1.22M
Cap. Flow %
0.41%
Top 10 Hldgs %
86.7%
Holding
20
New
1
Increased
12
Reduced
5
Closed
–
Avg Time Held
5.4 quarters
Top 10 Avg Time Held
3.1 quarters
Top 20 Avg Time Held
5.4 quarters

Top Buys

Rank Stock Value
1
CMPX icon
Compass Therapeutics
CMPX
+$10M
2
IMA icon
ImageneBio Inc
IMA
+$6.75M
3
CGEM icon
Cullinan Oncology
CGEM
+$4.63M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$3.92M
5
ONCR
Oncorus, Inc.
ONCR
+$2.72M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$34.7M
2
RPTX icon
Repare Therapeutics
RPTX
+$484K
3
DTIL icon
Precision BioSciences
DTIL
+$373K
4
INZY icon
Inozyme Pharma
INZY
+$244K
5
AKUS
Akouos Inc
AKUS
+$196K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$69.3M 23%
1,752,243
-1,109,816
-39% -$34.7M
2021 Q1
3 quarters
RPTX icon
2
DELISTED
Repare Therapeutics
RPTX
$46.7M 15.49%
2,212,256
-20,527
-0.9% -$484K
2020 Q2
6 quarters
CGEM icon
3
Cullinan Oncology
CGEM
$962M
$38.2M 12.68%
2,476,720
+231,879
+10% +$4.63M
2021 Q1
3 quarters
PLRX icon
4
Pliant Therapeutics
PLRX
$61.1M
$34.7M 11.51%
2,569,479
+84,755
+3% +$1.35M
2020 Q2
6 quarters
LRMR icon
5
Larimar Therapeutics
LRMR
$263M
$16.3M 5.43%
1,515,148
– –
2020 Q2
6 quarters
VECT
6
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$13.1M 4.36%
2,675,408
+82,806
+3% +$408K
2021 Q2
2 quarters
OMGA icon
7
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$12M 3.97%
1,055,882
– –
2021 Q3
1 quarter
ONCR
8
DELISTED
Oncorus, Inc.
ONCR
$11.1M 3.69%
2,106,903
+350,924
+20% +$2.72M
2020 Q4
4 quarters
IMA icon
9
ImageneBio Inc
IMA
$48.2M
$10.2M 3.39%
67,896
+41,646
+159% +$6.75M
2021 Q1
3 quarters
CMPX icon
10
Compass Therapeutics
CMPX
$169M
$9.59M 3.18%
+3,023,692
New +$10M
2021 Q4
0 quarters
ORTX
11
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$8.51M 2.83%
644,986
+236,789
+58% +$3.92M
2019 Q3
9 quarters
AKUS
12
DELISTED
Akouos Inc
AKUS
$7.11M 2.36%
836,120
-21,907
-3% -$196K
2020 Q2
6 quarters
INZY icon
13
DELISTED
Inozyme Pharma
INZY
$6.08M 2.02%
892,057
-28,207
-3% -$244K
2020 Q3
5 quarters
KZR icon
14
DELISTED
Kezar Life Sciences
KZR
$4.55M 1.51%
27,225
+19,725
+263% +$2.23M
2019 Q3
9 quarters
DTIL icon
15
Precision BioSciences
DTIL
$180M
$4.49M 1.49%
20,221
-1,337
-6% -$373K
2019 Q3
9 quarters
FRLN
16
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$3.71M 1.23%
125,093
+29,928
+31% +$1.22M
2020 Q3
5 quarters
GTHX icon
17
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.35M 0.78%
230,000
+180,000
+360% +$2.29M
2020 Q2
6 quarters
OVID icon
18
Ovid Therapeutics
OVID
$471M
$1.28M 0.43%
400,000
+166,490
+71% +$570K
2019 Q3
9 quarters
KROS icon
19
Keros Therapeutics
KROS
$230M
$1.02M 0.34%
17,518
+4,891
+39% +$244K
2020 Q2
6 quarters
CRVS icon
20
Corvus Pharmaceuticals
CRVS
$845M
$964K 0.32%
400,000
+234,073
+141% +$908K
2019 Q3
9 quarters

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, CHI Advisors held 20 positions worth $301M, down 12% from $343M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

CHI Advisors's Q4 2021 filing shows 1 new, 12 increased and 5 reduced positions. Its largest new stake was Compass Therapeutics: 3,023,692 shares worth $9.59M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $34.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • CHI Advisors's largest Q4 2021 buy was Compass Therapeutics: 3,023,692 shares worth $9.59M.
  • CHI Advisors added most to ImageneBio Inc in Q4 2021, an estimated $6.75M increase.
  • CHI Advisors's biggest Q4 2021 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $34.7M.
  • CHI Advisors's ten largest holdings make up 87% of its $301M portfolio in Q4 2021.
  • CHI Advisors opened 1 new position and closed 0 in Q4 2021.
  • CHI Advisors's portfolio value fell 12% quarter-over-quarter to $301M.

Based on CHI Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.